Trial Condition(s):
Anticoagulation preference by AF patients study (PRiSMA-AF)
18242
Not Available
Not Available
The main research question of this patient survey is to assess AF (Atrial Fibrillation) patients’ preferences associated with different attributes which describe the different available anticoagulation treatment options (Vitamin K Antagonists [VKA] or New Oral Anticoagulants [NOACs] and, in case of NOACs, Apixaban, Dabigatran, Edoxaban or Rivaroxaban).
VKAs (Marcoumar®, Sintrom ®) will be grouped together and compared to Rivaroxaban.
Inclusion criteria for AF patients in both the NOAC and the VKA groups: - Patients with a confirmed diagnosis of nonvalvular atrial fibrillation (persistent, paroxysmal, permanent), - Age of at least 18 years at time of study inclusion, - Generally willingness (informed consent) and ability to fill out a survey on satisfaction with treatment and quality of life, and to conduct a structured phone interview (approx. 20 - 30 min) in German language. Additional inclusion criterion for Group 1 (NOAC): - Continuous anticoagulation with either Apixaban, or Dabigatran or Rivaroxaban for prevention of Stroke & systemic embolism for at least the previous 3 months. Additional inclusion criterion for Group 2 (VKA): - Continuous anticoagulation with a VKA for prevention of Stroke & systemic embolism for at least the previous 3 months.
Exclusion criteria for both groups: - Participation in another study (clinical intervention / observational) within the 3 months prior to enrollment, - Interruption of VKA/NOAC therapy of more than 2 weeks (bridging) within the prior 3 months or planned bridging in 4 weeks after study inclusion.
Locations | Status | |
---|---|---|
Locations Investigative Site Many Locations, Switzerland | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
AF patient preferences towards NOAC versus VKA treatment: a patient preference study
Trial Type:
Observational
Intervention Type:
Other
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
2